“A ‘gamechanging’ drug that prevents hot flushes and could benefit hundreds of thousands of women has been approved for use in the UK.
The green light for Veoza, also known as fezolinetant, comes after the US regulator, the Food and Drug Administration, authorised it for use in America in May.”
From The Guardian.
“Under the program, the DOE will coordinate efforts across eight other agencies to prepare a single environmental review document for transmission developers seeking federal approvals. The program also establishes a two-year timeline for the permitting process.
‘The CITAP program gives transmission developers a new option for a more efficient review process, a major step to provide increased confidence for the sector to invest in new transmission lines,’ the DOE said in a fact sheet.
A second final rule creates a categorical exclusion — the simplest form of review under the National Environmental Policy Act — for transmission projects that use existing rights of way, such as reconductoring projects, as well as solar and energy storage projects on already disturbed lands.”
From S&P Global.
“Divorced couples in Japan will for the first time be able to negotiate joint custody of their children after parliament voted this week for changes to laws permitting only sole custody.”
From The Guardian.
Washington Post | Health & Medical Care
“Bobby Reddy Jr. roamed a hospital as he built his start-up, observing how patient care began with a diagnosis and followed a set protocol. The electrical engineer thought he knew a better way: an artificial intelligence tool that would individualize treatment.
Now, the Food and Drug Administration has greenlighted such a test developed by Reddy’s company, Chicago-based Prenosis, to predict the risk of sepsis — a complex condition that contributes to at least 350,000 deaths a year in the United States. It is the first algorithmic, AI-driven diagnostic tool for sepsis to receive the FDA’s go-ahead.”
From Washington Post.
